Harnessing olaparib, palbociclib, and endocrine therapy: A phase I/II trial of olaparib, palbociclib and fulvestrant in patients with BRCA mutation-associated, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (HOPE) Meeting Abstract
| Authors: | Torres, A.; Aaron, M.; White, L.; D'Andrea, K.; Narayan, V.; Knollman, H. M.; Bradbury, A. R.; Tung, N. M.; Robson, M. E.; Nathanson, K.; Domchek, S. M.; Shah, P. D. |
| Abstract Title: | Harnessing olaparib, palbociclib, and endocrine therapy: A phase I/II trial of olaparib, palbociclib and fulvestrant in patients with BRCA mutation-associated, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (HOPE) |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.TPS1126 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: TPS1126 -- Meeting was also available virtually -- Source: Cinahl |
